Insider Trading Alert - InterMune And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 4, 2013, 135 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $375.00 to $6,781,627.44.

Highlighted Stocks Traded by Insiders:

InterMune (ITMN) - FREE Research Report

Kabakoff David S who is Director at InterMune sold 10,002 shares at $14.82 on Sept. 4, 2013. Following this transaction, the Director owned 30,500 shares meaning that the stake was reduced by 24.7% with the 10,002 share transaction.

The shares most recently traded at $15.00, up $0.18, or 1.19% since the insider transaction.

The average volume for InterMune has been 1.3 million shares per day over the past 30 days. InterMune has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 54.7% year to date as of the close of trading on Wednesday.

InterMune, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases. The company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Currently there are 10 analysts that rate InterMune a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITMN - FREE

TheStreet Quant Ratings rates InterMune as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full InterMune Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Pandora Media (P) - FREE Research Report

Westergren Timothy who is Chief Strategy Off & Director at Pandora Media sold 85,000 shares at $18.64 on Sept. 4, 2013. Following this transaction, the Chief Strategy Off & Director owned 340,000 shares meaning that the stake was reduced by 20% with the 85,000 share transaction.

The shares most recently traded at $18.50, down $0.14, or 0.76% since the insider transaction.

The average volume for Pandora Media has been 7.0 million shares per day over the past 30 days. Pandora Media has a market cap of $3.3 billion and is part of the services sector and media industry. Shares are up 98.37% year to date as of the close of trading on Wednesday.

Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access unlimited hours of free music and comedy, as well as offers Pandora One, a paid subscription service to listeners. Currently there are 11 analysts that rate Pandora Media a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on P - FREE

TheStreet Quant Ratings rates Pandora Media as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Pandora Media Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

DexCom (DXCM) - FREE Research Report

Gregg Terrance H who is Ceo at DexCom sold 9,000 shares at $27.00 on Sept. 4, 2013. Following this transaction, the Ceo owned 759,889 shares meaning that the stake was reduced by 1.17% with the 9,000 share transaction.

The shares most recently traded at $26.77, down $0.23, or 0.86% since the insider transaction.

The average volume for DexCom has been 577,800 shares per day over the past 30 days. DexCom has a market cap of $1.9 billion and is part of the health care sector and health services industry. Shares are up 96.25% year to date as of the close of trading on Wednesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 7 analysts that rate DexCom a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Juniper Networks (JNPR) - FREE Research Report

Stensrud William who is Director at Juniper Networks sold 20,000 shares at $19.06 on Sept. 4, 2013. Following this transaction, the Director owned 311,867 shares meaning that the stake was reduced by 6.03% with the 20,000 share transaction.

The shares most recently traded at $20.57, up $1.51, or 7.35% since the insider transaction.

The average volume for Juniper Networks has been 5.4 million shares per day over the past 30 days. Juniper Networks has a market cap of $9.9 billion and is part of the technology sector and computer hardware industry. Shares are up 5.34% year to date as of the close of trading on Wednesday.

Juniper Networks, Inc. designs, develops, and sells products and services that provide network infrastructure for networking requirements of service providers, enterprises, governments, and research and public sector organizations worldwide. The company has a P/E ratio of 33.5. Currently there are 6 analysts that rate Juniper Networks a buy, 1 analyst rates it a sell, and 17 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JNPR - FREE

TheStreet Quant Ratings rates Juniper Networks as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Get the full Juniper Networks Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Anadarko Petroleum (APC) - FREE Research Report

Gordon John R who is Director at Anadarko Petroleum sold 20,000 shares at $92.50 on Sept. 4, 2013. Following this transaction, the Director owned 164,543 shares meaning that the stake was reduced by 10.84% with the 20,000 share transaction.

The shares most recently traded at $92.46, down $0.04, or 0.04% since the insider transaction.

The average volume for Anadarko Petroleum has been 2.8 million shares per day over the past 30 days. Anadarko Petroleum has a market cap of $46.5 billion and is part of the basic materials sector and energy industry. Shares are up 24.02% year to date as of the close of trading on Wednesday.

Anadarko Petroleum Corporation engages in the exploration, development, production, and marketing of natural gas, crude oil, condensate, and natural gas liquids (NGLs) in the United States and internationally. The stock currently has a dividend yield of 0.78%. The company has a P/E ratio of 27.4. Currently there are 17 analysts that rate Anadarko Petroleum a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on APC - FREE

TheStreet Quant Ratings rates Anadarko Petroleum as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, compelling growth in net income and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Anadarko Petroleum Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists